粪菌移植治疗肠易激综合征的疗效:系统评价与Meta分析
该系统评价与Meta分析检索MEDLINE、EMBASE、Cochrane对照试验中心注册库和Web of Science,纳入4项随机对照试验共254例肠易激综合征患者,比较粪菌移植与安慰剂(粪菌移植辅料或自体粪菌移植)。12周时粪菌移植组与安慰剂组整体症状改善无显著差异(RR=0.93,95%CI 0.48-1.79),研究间异质性显著(I=79%),证据质量极低。
要点
- 12周时粪菌移植与安慰剂相比,肠易激综合征整体症状改善无显著差异(RR=0.93,95%CI 0.48-1.79)。
- 亚组分析显示单次剂量经结肠镜和鼻空肠管粪菌移植较自体粪菌移植有获益(需治疗人数=5,RR=1.59,95%CI 1.06-2.39,I=0%)。
- 多剂量胶囊粪菌移植随机对照试验中改善可能性降低(需伤害人数=3,RR=0.54,95%CI 0.34-0.85,I=13%)。
核心结论
- 当前随机对照试验证据不支持粪菌移植改善肠易激综合征整体症状。
- 粪菌移植在肠易激综合征中的疗效仍存疑问,亚组分析中随机对照试验结果不一致缺乏清晰解释。
研究设计与样本
- 系统评价与Meta分析,检索MEDLINE、EMBASE、Cochrane对照试验中心注册库和Web of Science。
- 纳入标准为粪菌移植对比安慰剂(粪菌移植辅料或自体粪菌移植)治疗肠易激综合征的随机对照试验。
- 共识别742条文献,7条可能相关,最终4项研究共254例参与者符合纳入标准。
主要发现
- 12周时粪菌移植与安慰剂相比,肠易激综合征整体症状改善无显著差异(RR=0.93,95%CI 0.48-1.79)。
- 研究间异质性显著(I=79%)。
- 亚组分析显示单次剂量经结肠镜和鼻空肠管粪菌移植较自体粪菌移植安慰剂治疗有获益(需治疗人数=5,RR=1.59,95%CI 1.06-2.39,I=0%)。
- 多剂量胶囊粪菌移植随机对照试验中改善可能性降低(需伤害人数=3,RR=0.54,95%CI 0.34-0.85,I=13%)。
- 非口服粪菌移植随机对照试验安慰剂反应率为33.7%,胶囊粪菌移植随机对照试验为67.8%。
关键数值与推荐
- 主要结局为采用公认整合症状问卷或整体症状改善问题的二分反应测量的整体肠易激综合征症状改善。
- GRADE证据质量评级为极低。
临床怎么用
- 原文未据此给出推荐。
局限性
- 研究间异质性显著(I=79%)。
- GRADE证据质量评级为极低。
- 粪菌移植在肠易激综合征中的疗效仍存疑问。
- 亚组分析中随机对照试验结果不一致缺乏清晰解释。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Irritable bowel syndrome (IBS) is a common gastrointestinal condition with a heterogeneous pathophysiology. An altered gut microbiome has been identified in some IBS patients, and fecal microbiota transplantation (FMT) has been suggested to treat IBS. We performed meta-analyses and systematic review of available randomized controlled trials (RCTs) to evaluate the efficacy of FMT in IBS. METHODS: We performed a systematic literature search of MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and Web of Science. Selection criteria included RCTs of FMT vs placebo using FMT excipients or autologous FMT in IBS. Meta-analyses were conducted to evaluate the summary relative risk (RR) and 95% confidence intervals (CIs) of combined studies for primary outcome of improvement in global IBS symptoms as measured by accepted integrative symptom questionnaires or dichotomous responses to questions of overall symptom improvement. RESULTS: Among 742 citations identified, 7 were deemed to be potentially relevant, of which 4 studies involving 254 participants met eligibility. No significant difference in global improvement of IBS symptoms was observed at 12 weeks in FMT vs placebo (RR = 0.93; 95% CI 0.48-1.79). Heterogeneity among studies was significant (I = 79%). Subgroup analyses revealed benefits of single-dose FMT using colonoscopy and nasojejunal tubes in comparison with autologous FMT for placebo treatment (number needed to treat = 5, RR = 1.59; 95% CI 1.06-2.39; I = 0%) and a reduction in likelihood of improvement of multiple-dose capsule FMT RCTs (number needed to harm = 3, RR = 0.54; 95% CI 0.34-0.85; I = 13%). Placebo response was 33.7% in nonoral FMT RCTs and 67.8% in capsule FMT RCTs. The Grading of Recommendations Assessment, Development and Evaluation quality of the body of evidence was very low. DISCUSSION: Current evidence from RCTs does not suggest a benefit of FMT for global IBS symptoms. There remain questions regarding the efficacy of FMT in IBS as well as the lack of a clean explanation on the discrepant results among RCTs in subgroup analyses.
引用
- Xu D, Chen VL, Steiner CA, et al. Efficacy of Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2019. PMID: 30908299. doi:10.14309/ajg.0000000000000198
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。